Nantahala Capital Management LLC Makes New Investment in Artiva Biotherapeutics, Inc. $ARTV

Nantahala Capital Management LLC bought a new position in shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 300,000 shares of the company’s stock, valued at approximately $2,910,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ARTV. 5AM Venture Management LLC acquired a new stake in shares of Artiva Biotherapeutics in the second quarter valued at $22,827,049. ADAR1 Capital Management LLC purchased a new position in Artiva Biotherapeutics in the second quarter valued at $1,151,000. Blue Owl Capital Holdings LP acquired a new position in Artiva Biotherapeutics during the 2nd quarter worth $8,483,000. BlackRock Inc. acquired a new position in Artiva Biotherapeutics during the 2nd quarter worth $6,739,000. Finally, State of Wyoming purchased a new stake in Artiva Biotherapeutics during the 2nd quarter worth about $45,000.

Artiva Biotherapeutics Stock Performance

ARTV opened at $11.09 on Friday. Artiva Biotherapeutics, Inc. has a one year low of $2.22 and a one year high of $14.53. The stock has a market capitalization of $542.19 million, a P/E ratio of -3.36 and a beta of 2.16. The business’s 50-day simple moving average is $10.38 and its 200-day simple moving average is $8.49.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its earnings results on Thursday, August 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.63). On average, equities research analysts forecast that Artiva Biotherapeutics, Inc. will post -2.62 EPS for the current fiscal year.

Insider Activity at Artiva Biotherapeutics

In other news, Director Ra Capital Management, L.P. acquired 24,944 shares of the business’s stock in a transaction on Friday, July 31st. The stock was bought at an average price of $9.93 per share, for a total transaction of $247,693.92. Following the transaction, the director owned 17,329,570 shares in the company, valued at $172,082,630.10. This represents a 0.14% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders purchased a total of 1,965,251 shares of company stock worth $16,188,035 in the last three months. 1.80% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. HC Wainwright increased their price target on Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, July 21st. Cantor Fitzgerald restated an “overweight” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, May 26th. Needham & Company LLC reaffirmed a “buy” rating and issued a $41.00 target price on shares of Artiva Biotherapeutics in a report on Monday, June 8th. Finally, Wedbush lifted their price target on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research note on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Artiva Biotherapeutics has an average rating of “Moderate Buy” and a consensus price target of $39.00.

Artiva Biotherapeutics Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.